The Effect of Spironolactone on Pain in Older People With Osteoarthritis (SPIR-OA)
A Randomised Placebo Controlled Trial. The Effect of Spironolactone on Pain in Older People With Osteoarthritis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Fife
-
Kirkcaldy, Fife, United Kingdom, KY2 5AH
- NHS Fife
-
-
Tayside
-
Dundee, Tayside, United Kingdom, DD1 9SY
- NHS Tayside
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participant is willing and able to give informed consent
- Community dwelling
- Aged 70 years and over
- Symptomatic idiopathic OA knee according to American College of Rheumatology clinical and radiographic criteria (ie Knee pain - with or without crepitus and presence of osteophytes on x ray)
- To avoid floor effects, participants will require to have moderate (or more severe) pain at screening in at least 2 out of 5 WOMAC pain score items
- To have been in receipt (prescription or/and over the counter) of one or more analgesic agents at a therapeutic dose for at least 2 months
- Willing to have knee x-ray if one has not been taken in preceding 12 months
Exclusion Criteria:
- Clinical diagnosis of symptomatic heart failure
- History of inflammatory arthritis
- Already taking spironolactone
- Previous intolerance to spironolactone
- Known allergies to spironolactone or lactose
- Objection to taking capsules made from animal sourced gelatine
- Taking oral NSAIDs (because of the increased risk of renal impairment when combined with spironolactone)
- Taking ACE inhibitors or ARBs (angiotensin II receptor antagonists). ARBs have many properties similar to those of ACE inhibitors. Both will be exclusion because of the increased risk of acute kidney injury and hyperkalaemia, and because our previous study also excluded those on ACE inhibitors (and ARBs) and treatment was safe and well tolerated.
- Supine hypotension (supine systolic blood pressure <100mmHg at screening)
- Significant chronic kidney disease (eGFR<40ml/min)
- Serum sodium<130mmol/l
- Serum potassium>5.0mmol/l
- Symptomatic orthostatic hypotension (measured at screening)
- Nursing home resident
- Wheelchair bound
- Participating in another clinical trial (other than observational trials and registries) concurrently or within 30 days prior to screening for entry into this study
- Known contraindication to spironolactone therapy
- Participant who is terminally ill, defined as less than 3 months expected survival
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Matched Placebo
|
spironolactone 25mg daily for 12 weeks
Other Names:
|
|
Active Comparator: spironolactone
25mg spironolactone daily
|
spironolactone 25mg daily for 12 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Between group difference in change in WOMAC pain subscale (5 items)
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Between group difference in change in WOMAC stiffness subscale.
Time Frame: 12 weeks
|
12 weeks
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Between group difference in change in WOMAC physical function subscales.
Time Frame: 12 weeks
|
12 weeks
|
|
Between group difference in change in health-related quality of life measured by EQ-5D questionnaire.
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Marion ET McMurdo, MBChB, MD, University of Dundee
- Principal Investigator: Miles Witham, BM BCh, MRCP, University of Dundee
- Principal Investigator: Vera Cvoro, Mb CHB, MRCP, NHS Fife
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Arthritis
- Osteoarthritis
- Osteoarthritis, Knee
- Physiological Effects of Drugs
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Natriuretic Agents
- Diuretics
- Hormone Antagonists
- Mineralocorticoid Receptor Antagonists
- Diuretics, Potassium Sparing
- Spironolactone
Other Study ID Numbers
Other Study ID Numbers
- 13/WS/0232
- 2013-002638-19 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.